The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition

Journal of Molecular Signaling

Volumn 5, Issue , 2010, Pages

  Tang, Su Ni ^a   Singh, Chandan ^a   Nall, Dara ^a   Meeker, Daniel ^a   Shankar, Sharmila ^a   Srivastava, Rakesh K ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROPODA;

EID: 77955641868     PISSN: None     EISSN: 17502187     Source Type: Journal    
DOI: 10.1186/1750-2187-5-14     Document Type: Article

References (150)

1. American Cancer Society Cancer Statistics. 2009, American.
2. Institute NC Defeating prostate cancer: Crucial directions for research. Report of the Prostate Cancer Progress Review Group. 1998, Institute NC.
3. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007, 18:460-466. 10.1016/j.copbio.2007.10.007, 18023337.
4. Er O. Cancer stem cells in solid tumors. Onkologie 2009, 32:605-609. 10.1159/000232375, 19816080.
5. Lang SH, Anderson E, Fordham R, Collins AT. Modeling the prostate stem cell niche: an evaluation of stem cell survival and expansion in vitro. Stem Cells Dev 2010, 19:537-546. 10.1089/scd.2009.0291, 20102283.
6. An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells?. Expert Opin Drug Metab Toxicol 2009, 5:1529-1542. 10.1517/17425250903228834, 19708828.
7. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009, 14:3-9. 10.1007/s10911-009-9109-9, 19224345.
8. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284. 10.1038/nrc1590, 15803154.
9. Deng CH, Zhang QP. Leukemia stem cells in drug resistance and metastasis. Chin Med J (Engl) 2010, 123:954-960.
10. Drewa T, Styczynski J. Can conception of prostate cancer stem cells influence treatment dedicated to patients with disseminated disease?. Med Hypotheses 2008, 71:694-699. 10.1016/j.mehy.2008.06.021, 18706770.
11. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008, 26:2862-2870. 10.1200/JCO.2007.15.1472, 18539965.
12. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008, 68:3243-3250. 10.1158/0008-5472.CAN-07-5480, 18451150.
13. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010,
14. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004, 23:7274-7282. 10.1038/sj.onc.1207947, 15378087.
15. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
16. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401. 10.1038/nature03128, 15549107.
17. Wang B, Yang H, Huang YZ, Yan RH, Liu FJ, Zhang JN. Biologic characteristics of the side population of human small cell lung cancer cell line H446. Chin J Cancer 2010, 29:254-260.
18. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115. 10.1038/nature05384, 17122771.
19. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121:823-835. 10.1016/j.cell.2005.03.032, 15960971.
20. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951. 10.1158/0008-5472.CAN-05-2018, 16322242.
21. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007, 20:102-107. 10.1038/modpathol.3800720, 17143262.
22. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005, 65:4320-4333. 10.1158/0008-5472.CAN-04-3327, 15899824.
23. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758. 10.1038/sj.onc.1210811, 17891174.
24. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008, 8:545-554. 10.1038/nrc2419, 18511937.
25. Sakariassen PO, Immervoll H, Chekenya M. Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia 2007, 9:882-892. 10.1593/neo.07658, 2077879, 18030356.
26. Al-Assar O, Muschel RJ, Mantoni TS, McKenna WG, Brunner TB. Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys 2009, 75:1216-1225.
27. Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 2010, 76:889-895.
28. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006, 98:1755-1757. 10.1093/jnci/djj505, 17179471.
29. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, Bapat SA. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009, 27:2059-2068. 10.1002/stem.154, 19544473.
30. Lomonaco SL, Finniss S, Xiang C, Decarvalho A, Umansky F, Kalkanis SN, Mikkelsen T, Brodie C. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009, 125:717-722. 10.1002/ijc.24402, 19431142.
31. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010, 28:17-28.
32. Gu Y, Kim KH, Ko D, Nakamura K, Yasunaga Y, Moul JW, Srivastava S, Arnstein P, Rhim JS. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. Int J Oncol 2004, 25:1057-1064.
33. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007, 67:4807-4815. 10.1158/0008-5472.CAN-06-4608, 17510410.
34. Collins CA, Olsen I, Zammit PS, Heslop L, Petrie A, Partridge TA, Morgan JE. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell 2005, 122:289-301. 10.1016/j.cell.2005.05.010, 16051152.
35. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005, 65:6207-6219. 10.1158/0008-5472.CAN-05-0592, 16024622.
36. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang LS, Yang Q, Huang J. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009, 69:787-798. 10.1002/pros.20928, 19189306.
37. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25:1696-1708. 10.1038/sj.onc.1209327, 16449977.
38. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med 2006, 12:296-300. 10.1038/nm1379, 16520777.
39. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality?. Nat Med 2009, 15:1010-1012. 10.1038/nm0909-1010, 19734877.
40. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009, 26:433-446. 10.1007/s10585-009-9242-2, 2782741, 19221883.
41. Sarkar FH, Li Y, Wang Z, Kong D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir 2009, 64:489-500.
42. Androutsopoulos VP, Papakyriakou A, Vourloumis D, Tsatsakis AM, Spandidos DA. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol Ther 2010, 126:9-20. 10.1016/j.pharmthera.2010.01.009, 20153368.
43. Fresco P, Borges F, Marques MP, Diniz C. The anticancer properties of dietary polyphenols and its relation with apoptosis. Curr Pharm Des 2010, 16:114-134. 10.2174/138161210789941856, 20214622.
44. Gilbert ER, Liu D. Flavonoids influence epigenetic-modifying enzyme activity: structure-function relationships and the therapeutic potential for cancer. Curr Med Chem 2010, 17:1756-1768. 10.2174/092986710791111161, 20345345.
45. Guo W, Kong E, Meydani M. Dietary polyphenols, inflammation, and cancer. Nutr Cancer 2009, 61:807-810. 10.1080/01635580903285098, 20155620.
46. Lamoral-Theys D, Pottier L, Dufrasne F, Neve J, Dubois J, Kornienko A, Kiss R, Ingrassia L. Natural polyphenols that display anticancer properties through inhibition of kinase activity. Curr Med Chem 2010, 17:812-825. 10.2174/092986710790712183, 20156174.
47. Liu HL, Jiang WB, Xie MX. Flavonoids: recent advances as anticancer drugs. Recent Pat Anticancer Drug Discov 2010, 5:152-164. 10.2174/157489210790936261, 20088766.
48. Khan N, Adhami VM, Mukhtar H. Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer 2009, 61:836-841. 10.1080/01635580903285056, 20155624.
49. Khan N, Adhami VM, Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer 2010, 17:R39-52. 10.1677/ERC-09-0262, 19926708.
50. Prasad S, Phromnoi K, Yadav VR, Chaturvedi MM, Aggarwal BB. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med 2010, 76:1044-1063. 10.1055/s-0030-1250111, 20635307.
51. Huang WY, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer 2010, 62:1-20. 10.1080/01635580903191585, 20043255.
52. Lamson DW, Brignall MS. Antioxidants and cancer, part 3: quercetin. Altern Med Rev 2000, 5:196-208.
53. Davis JM, Murphy EA, Carmichael MD. Effects of the dietary flavonoid quercetin upon performance and health. Curr Sports Med Rep 2009, 8:206-213.
54. Hirpara KV, Aggarwal P, Mukherjee AJ, Joshi N, Burman AC. Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anticancer Agents Med Chem 2009, 9:138-161.
55. Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A. Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem 2009, 16:1451-1462. 10.2174/092986709787909578, 19355899.
56. Mainardi T, Kapoor S, Bielory L. Complementary and alternative medicine: herbs, phytochemicals and vitamins and their immunologic effects. J Allergy Clin Immunol 2009, 123:283-294. quiz 295-286, 10.1016/j.jaci.2008.12.023, 19203652.
57. Ishii K, Tanaka S, Kagami K, Henmi K, Toyoda H, Kaise T, Hirano T. Effects of naturally occurring polymethyoxyflavonoids on cell growth, p-glycoprotein function, cell cycle, and apoptosis of daunorubicin-resistant T lymphoblastoid leukemia cells. Cancer Invest 2010, 28:220-229. 10.3109/07357900902744486, 19863351.
58. Lee TJ, Kim OH, Kim YH, Lim JH, Kim S, Park JW, Kwon TK. Quercetin arrests G2/M phase and induces caspase-dependent cell death in U937 cells. Cancer Lett 2006, 240:234-242. 10.1016/j.canlet.2005.09.013, 16274926.
59. Suh DK, Lee EJ, Kim HC, Kim JH. Induction of G(1)/S phase arrest and apoptosis by quercetin in human osteosarcoma cells. Arch Pharm Res 2010, 33:781-785. 10.1007/s12272-010-0519-4, 20512478.
60. Chien SY, Wu YC, Chung JG, Yang JS, Lu HF, Tsou MF, Wood WG, Kuo SJ, Chen DR. Quercetin-induced apoptosis acts through mitochondrial- and caspase-3-dependent pathways in human breast cancer MDA-MB- cells. Hum Exp Toxicol 2009, 28:493-503. 10.1177/0960327109107002, 19755441.
61. Granado-Serrano AB, Martin MA, Bravo L, Goya L, Ramos S. Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr 2006, 136:2715-2721.
62. Zhang Q, Zhao XH, Wang ZJ. Cytotoxicity of flavones and flavonols to a human esophageal squamous cell carcinoma cell line (KYSE-510) by induction of G2/M arrest and apoptosis. Toxicol In Vitro 2009, 23:797-807. 10.1016/j.tiv.2009.04.007, 19397994.
63. Kim MK, Jung HS, Yoon CS, Ko JH, Chun HJ, Kim TK, Kwon MJ, Lee SH, Koh KS, Rhee BD, Park JH. EGCG and quercetin protected INS-1 cells in oxidative stress via different mechanisms. Front Biosci (Elite Ed) 2010, 2:810-817. 10.2741/E142, 20515754.
64. Sun ZJ, Chen G, Hu X, Zhang W, Liu Y, Zhu LX, Zhou Q, Zhao YF. Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis 2010, 15:850-863. 10.1007/s10495-010-0497-5, 20386985.
65. Aghdassi A, Phillips P, Dudeja V, Dhaulakhandi D, Sharif R, Dawra R, Lerch MM, Saluja A. Heat shock protein increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res 2007, 67:616-625. 10.1158/0008-5472.CAN-06-1567, 17234771.
66. Borska S, Sopel M, Chmielewska M, Zabel M, Dziegiel P. Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 2010, 15:857-870. 10.3390/molecules15020857, 20335952.
67. Chung SY, Sung MK, Kim NH, Jang JO, Go EJ, Lee HJ. Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res 2005, 28:823-828. 10.1007/BF02977349, 16114498.
68. Du G, Lin H, Yang Y, Zhang S, Wu X, Wang M, Ji L, Lu L, Yu L, Han G. Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice. Int Immunopharmacol 2010, 10(7):819-26. 10.1016/j.intimp.2010.04.018, 20447470.
69. Shih YL, Liu HC, Chen CS, Hsu CH, Pan MH, Chang HW, Chang CH, Chen FC, Ho CT, Yang YY, Ho YS. Combination treatment with luteolin and quercetin enhances antiproliferative effects in nicotine-treated MDA-MB-231 cells by down-regulating nicotinic acetylcholine receptors. J Agric Food Chem 2010, 58:235-241. 10.1021/jf9031684, 19921817.
70. Wong MY, Chiu GN. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment. Anticancer Drugs 2010, 21:401-410. 10.1097/CAD.0b013e328336e940, 20110806.
71. Tang GQ, Yan TQ, Guo W, Ren TT, Peng CL, Zhao H, Lu XC, Zhao FL, Han X. (-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells. J Cancer Res Clin Oncol 2010, 136:1179-1185. 10.1007/s00432-010-0765-3, 20127255.
72. Britschgi A, Simon HU, Tobler A, Fey MF, Tschan MP. Epigallocatechin-3-gallate induces cell death in acute myeloid leukaemia cells and supports all-trans retinoic acid-induced neutrophil differentiation via death-associated protein kinase 2. Br J Haematol 2010, 149:55-64. 10.1111/j.1365-2141.2009.08040.x, 20096012.
73. Aboulaila M, Yokoyama N, Igarashi I. Inhibitory effects of (-)-epigallocatechin-3-gallate from green tea on the growth of Babesia parasites. Parasitology 2010, 137:785-791. 10.1017/S0031182009991594, 20025823.
74. Johnson JJ, Bailey HH, Mukhtar H. Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine 2010, 17:3-13. 10.1016/j.phymed.2009.09.011, 19959000.
75. Manson MM, Farmer PB, Gescher A, Steward WP. Innovative agents in cancer prevention. Recent Results Cancer Res 2005, 166:257-275. full_text, 15648195.
76. Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 2010, 17:356-362. 10.1016/j.phymed.2010.01.001, 20149610.
77. Shankar S, Ganapathy S, Hingorani SR, Srivastava RK. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 2008, 13:440-452. 10.2741/2691, 17981559.
78. Shankar S, Ganapathy S, Srivastava RK. Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci 2007, 12:4881-4899. 10.2741/2435, 17569617.
79. Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 2003, 133:2417S-2424S.
80. Ahmad KA, Harris NH, Johnson AD, Lindvall HC, Wang G, Ahmed K. Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Mol Cancer Ther 2007, 6:1006-1012. 10.1158/1535-7163.MCT-06-0491, 17363494.
81. Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys 2000, 376:338-346. 10.1006/abbi.2000.1742, 10775421.
82. Borska S, Gebarowska E, Wysocka T, Drag-Zalesinska M, Zabel M. Induction of apoptosis by EGCG in selected tumour cell lines in vitro. Folia Histochem Cytobiol 2003, 41:229-232.
83. Chung LY, Cheung TC, Kong SK, Fung KP, Choy YM, Chan ZY, Kwok TT. Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells. Life Sci 2001, 68:1207-1214. 10.1016/S0024-3205(00)01020-1, 11228105.
84. Shankar S, Suthakar G, Srivastava RK. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci 2007, 12:5039-5051. 10.2741/2446, 17569628.
85. Collins AT, Maitland NJ. Prostate cancer: regeneration of interest in the prostate. Nat Rev Urol 2009, 6:184-186. 10.1038/nrurol.2009.48, 19352391.
86. Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 2009, 19:683-697. 10.1038/cr.2009.43, 19365403.
87. Pfeiffer MJ, Schalken JA. Stem cell characteristics in prostate cancer cell lines. Eur Urol 2010, 57:246-254. 10.1016/j.eururo.2009.01.015, 19200636.
88. Mueller MT, Hermann PC, Heeschen C. Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci (Elite Ed) 2010, 2:602-613.
89. Ratajczak M, Tarnowski M, Staniszewska M, Sroczynski T, Banach B. Mechanisms of cancer metastasis: involvement of cancer stem cells?. Minerva Med 2010, 101:179-191.
90. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes OCT 4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005, 104:2255-2265. 10.1002/cncr.21432, 16228988.
91. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, Calhoun-Davis T, Zaehres H, Daley GQ, Tang DG. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009, 27:993-1005. 10.1002/stem.29, 19415763.
92. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003, 113:631-642. 10.1016/S0092-8674(03)00393-3, 12787504.
93. Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski JT, Kelley V, Jorgensen M, Steindler DA, Vieweg J, Siemann DW. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010, 183:2045-2053. 10.1016/j.juro.2009.12.092, 20303530.
94. Gauthaman K, Fong CY, Bongso A. Statins, stem cells, and cancer. J Cell Biochem 2009, 106:975-983. 10.1002/jcb.22092, 19224538.
95. Hubbard SA, Friel AM, Kumar B, Zhang L, Rueda BR, Gargett CE. Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res 2009, 69:8241-8248. 10.1158/0008-5472.CAN-08-4808, 19843861.
96. Ji J, Werbowetski-Ogilvie TE, Zhong B, Hong SH, Bhatia M. Pluripotent transcription factors possess distinct roles in normal versus transformed human stem cells. PLoS One 2009, 4:e8065. 10.1371/journal.pone.0008065, 2778551, 19956629.
97. Wang L, Park P, Lin CY. Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol Ther 2009, 8:6.
98. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001, 3:535-546. 10.1038/sj.neo.7900203, 1506567, 11774036.
99. Srivastava RK. Intracellular mechanisms of TRAIL and its role in cancer therapy. Mol Cell Biol Res Commun 2000, 4:67-75. 10.1006/mcbr.2001.0265, 11170835.
100. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890. 10.1016/j.cell.2009.11.007, 19945376.
101. Creighton CJ, Chang JC, Rosen JM. Epithelial-Mesenchymal Transition (EMT) in Tumor-Initiating Cells and Its Clinical Implications in Breast Cancer. J Mammary Gland Biol Neoplasia 2010, 15(2):253-60. 10.1007/s10911-010-9173-1, 20354771.
102. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010, 101:293-299. 10.1111/j.1349-7006.2009.01419.x, 19961486.
103. Wu Y, Zhou BP. Snail: More than EMT. Cell Adh Migr 2010, 4(2):199-203. 10.4161/cam.4.2.10943, 20168078.
104. Du G, Lin H, Wang M, Zhang S, Wu X, Lu L, Ji L, Yu L. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1alpha in tumor and normal cells. Cancer Chemother Pharmacol 2009,
105. Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005, 17:86-95.
106. Russo M, Spagnuolo C, Volpe S, Mupo A, Tedesco I, Russo GL. Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients. Br J Cancer 2010,
107. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 2008, 68:1820-1825. 10.1158/0008-5472.CAN-07-5878, 18339862.
108. Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN, Cecchini MG. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 2009, 69:1683-1693. 10.1002/pros.21018, 19644960.
109. Clarke MF. What can we learn about breast cancer from stem cells?. Adv Exp Med Biol 2008, 617:17-22. full_text, 18497027.
110. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008, 10:R25. 10.1186/bcr1982, 2397524, 18366788.
111. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648. 10.1038/367645a0, 7509044.
112. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
113. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol 2008, 26:2806-2812. 10.1200/JCO.2008.16.6702, 18539958.
114. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010, 5:e10277. 10.1371/journal.pone.0010277, 2858084, 20422001.
115. Hermann PC, Bhaskar S, Cioffi M, Heeschen C. Cancer stem cells in solid tumors. Semin Cancer Biol 2010, 20:77-84. 10.1016/j.semcancer.2010.03.004, 20371287.
116. Papailiou J, Bramis KJ, Gazouli M, Theodoropoulos G. Stem cells in colon cancer. A new era in cancer theory begins. Int J Colorectal Dis 2010,
117. Saif MW, Chu E. Biology of colorectal cancer. Cancer J 2010, 16:196-201. 10.1097/PPO.0b013e3181e076af, 20526096.
118. Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer 2006, 42:1213-1218. 10.1016/j.ejca.2006.01.037, 16632344.
119. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F, Thalman G. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 2010, 70:875-882.
120. Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 2008, 4:697-720. 10.1517/17425255.4.6.697, 2658643, 18611112.
121. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
122. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010, 16:45-55. 10.1158/1078-0432.CCR-09-1630, 20028757.
123. Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, Stass SA, Jiang F. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010, 90:234-244. 10.1038/labinvest.2009.127, 20010854.
124. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69:3382-3389. 10.1158/0008-5472.CAN-08-4418, 2789401, 19336570.
125. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009, 178:48-55. 10.1016/j.cbi.2008.09.029, 18952074.
126. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-Ramirez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010, 70:5163-5173. 10.1158/0008-5472.CAN-09-3806, 20516116.
127. Hwang MK, Song NR, Kang NJ, Lee KW, Lee HJ. Activation of phosphatidylinositol 3-kinase is required for tumor necrosis factor-alpha-induced upregulation of matrix metalloproteinase-9: its direct inhibition by quercetin. Int J Biochem Cell Biol 2009, 41:1592-1600. 10.1016/j.biocel.2009.01.014, 19401153.
128. Chen W, Wang X, Zhuang J, Zhang L, Lin Y. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis 2007, 28:2114-2121. 10.1093/carcin/bgm133, 17548900.
129. Jung YH, Heo J, Lee YJ, Kwon TK, Kim YH. Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci 2010, 86:351-357. 10.1016/j.lfs.2010.01.008, 20096292.
130. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 2007, 6:2591-2599. 10.1158/1535-7163.MCT-07-0001, 17876056.
131. Howells LM, Britton RG, Mazzoletti M, Greaves P, Broggini M, Brown K, Steward WP, Gescher AJ, Sale S. Preclinical Colorectal Cancer Chemopreventive Efficacy and p53-Modulating Activity of 3',4',5'-Trimethoxyflavonol, a Quercetin Analogue. Cancer Prev Res (Phila Pa) 2010, 3(8):929-39.
132. Hsieh TC, Wu JM. Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res 2009, 29:4025-4032.
133. Thangasamy T, Sittadjody S, Mitchell GC, Mendoza EE, Radhakrishnan VM, Limesand KH, Burd R. Quercetin abrogates chemoresistance in melanoma cells by modulating DeltaNp73. BMC Cancer 2010, 10:282. 10.1186/1471-2407-10-282, 2895613, 20540768.
134. Tokalov SV, Abramyuk AM, Abolmaali ND. Protection of p53 Wild Type Cells From Taxol by Genistein in the Combined Treatment of Lung Cancer. Nutr Cancer 2010, 62:795-801. 10.1080/01635581003605912, 20661829.
135. Chen C, Zhou J, Ji C. Quercetin: A potential drug to reverse multidrug resistance. Life Sci 2010,
136. Suttana W, Mankhetkorn S, Poompimon W, Palagani A, Zhokhov S, Gerlo S, Haegeman G, Berghe WV. Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols. Mol Cancer 2010, 9:99. 10.1186/1476-4598-9-99, 2873443, 20438634.
137. Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, Robson P. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem 2005, 280:24731-24737. 10.1074/jbc.M502573200, 15860457.
138. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122:947-956. 10.1016/j.cell.2005.08.020, 16153702.
139. Kuroda T, Tada M, Kubota H, Kimura H, Hatano SY, Suemori H, Nakatsuji N, Tada T. Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. Mol Cell Biol 2005, 25:2475-2485. 10.1128/MCB.25.6.2475-2485.2005, 1061601, 15743839.
140. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003, 113:643-655. 10.1016/S0092-8674(03)00392-1, 12787505.
141. Hoei-Hansen CE, Nielsen JE, Almstrup K, Hansen MA, Skakkebaek NE, Rajpert-DeMeyts E, Leffers H. Identification of genes differentially expressed in testes containing carcinoma in situ. Mol Hum Reprod 2004, 10:423-431. 10.1093/molehr/gah059, 15123780.
142. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JF. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 2008, 14:4085-4095. 10.1158/1078-0432.CCR-07-4404, 18593985.
143. Lu KH, Chen YW, Tsai PH, Tsai ML, Lee YY, Chiang CY, Kao CL, Chiou SH, Ku HH, Lin CH, Chen YJ. Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells. Childs Nerv Syst 2009, 25:543-550. 10.1007/s00381-009-0826-6, 19225784.
144. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037. 10.1158/0008-5472.CAN-06-2030, 17283135.
145. Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol 2009, 568:161-173. full_text, 19582426.
146. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003, 423:409-414. 10.1038/nature01593, 12717450.
147. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998, 72:8463-8471. 110254, 9765382.
148. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787. 10.1126/science.275.5307.1784, 9065401.
149. Shankar S, Ganapathy S, Srivastava RK. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res 2008, 14:6855-6866. 10.1158/1078-0432.CCR-08-0903, 18980980.
150. Shankar S, Siddiqui I, Srivastava RK. Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem 2007, 304:273-285. 10.1007/s11010-007-9510-x, 17636462.